Less than a month after unveiling a peptide expansion at its production site in Mourenx, CDMO Axplora has hit the gas on a ...

Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and ...

Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human ...

Antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic agents, offer a targeted approach to cancer therapy, aiming to deliver ...

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

Arrivent Biopharma, Inc. (NASDAQ: AVBP) has reported its financial results for the full year 2024 and highlighted recent ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

We were very pleased that the private placement was supported by existing investors and our Board of Directors, all of whom participated in this financing,” said Samir R. Patel, MD, President and CEO ...

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs ...